Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus = Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus

다국어 초록 (Multilingual Abstract)

Background/Aims: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contributing to a sustained virologic response (SVR). Methods: One hundred IFN ineligible patients infected with genotype 1b hepatitis C virus (HCV) were treated. Simeprevir (100 mg) was given orally together with reduced doses of PEG-IFN-α 2a (90 μg), and ribavirin (200 mg less than the recommended dose). Results: The patients` median age was 70 years, and 70 patients were cirrhotic. Three patients (3%) discontinued treatment due to adverse events. The SVR rate was 64%. Factors that significantly contributed to the SVR included the γ-glutamyl transferase and α-fetoprotein levels, interleukin- 28B (IL28B) polymorphism status, and the level and reduction of HCV RNA at weeks 2 and 4. The multivariate analysis showed that the IL28B polymorphism status was the only independent factor that predicted the SVR, with a positive predictive value of 77%. Conclusions: Simeprevir-based triple therapy with reduced doses of PEG-IFN and ribavirin was safe and effective for IFN ineligible patients infected with genotype 1b HCV. IL28B polymorphism status was a useful predictor of the SVR. (Gut Liver 2017;11:551-558)

참고문헌 (Reference)

• 1 Hayashi K, "Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population" 12 : 106-110, 2005
• 2 Tahata Y, "The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin" 51 : 252-259, 2016
• 3 Kumada H, "Telaprevir with peginterferon and ribavirin for treatment- naive patients chronically infected with HCV of genotype 1 in Japan" 56 : 78-84, 2012
• 4 Jacobson IM, "Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial" 384 : 403-413, 2014
• 5 Manns M, "Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial" 384 : 414-426, 2014
• 6 Hayashi N, "Simeprevir with peginterferon/ ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial" 61 : 219-227, 2014
• 7 Reddy KR, "Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial" 15 : 27-35, 2015
• 8 Bota S, "Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review" 5 : 120-126, 2013
• 9 Roomer R, "Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C" 52 : 1225-1231, 2010
• 10 Tamai H, "Prediction of sustained virological response to telaprevir-based triple therapy using viral response within 2 weeks" 2014 : 748935-, 2014
• 11 Tamai H, "Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation" 41 : 1137-1144, 2011
• 12 Roffi L, "Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis" 13 : 663-673, 2008
• 13 Di Marco V, "Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial" 47 : 484-491, 2007
• 14 Izumi N, "Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO- 3 studies" 49 : 941-953, 2014
• 15 Fried MW, "Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study" 58 : 1918-1929, 2013
• 16 Enomoto N, "Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection" 334 : 77-81, 1996
• 17 Tamai H, "Low-dose pegylated interferon- alpha2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load" 19 : 107-115, 2014
• 18 Tahata Y, "Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy" 88 : 1776-1784, 2016
• 19 Editors of the Drafting Committee for Hepatitis Management Guidelines: the Japan Society of Hepatology, "Guidelines for the management of hepatitis c virus infection: first edition, May 2012, The Japan Society of Hepatology" 43 : 1-34, 2013
• 20 Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C" 41 : 1105-1109, 2009
• 21 Huang CF, "Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C" 201 : 751-759, 2010
• 22 Bruno S, "Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis" 51 : 388-397, 2010
• 23 Ogawa E, "Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure" 22 : 992-1001, 2015
• 24 Asahina Y, "Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection" 52 : 518-527, 2010
• 25 Ogawa E, "Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C" 30 : 1309-1316, 2015
• 26 Ogawa E, "Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection" 30 : 1759-1767, 2015
• 27 Simmonds P, "Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region" 74 (74): 2391-2399, 1993
• 28 Akuta N, "Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferonribavirin combination therapy" 48 : 372-380, 2005